Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral
selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the
tolerability and the best dose of Fluzoparib in combination with apatinib and paclitaxel and
to see how well this three drugs work together in the treatment of patients with recurrent
and metastatic gastric cancer who progress following first-line therapy. The safety and
efficacy of fluzoparib in combination with apatinib and paclitaxel will be explored.